Seagen Looks To Nix Daiichi Win In Cancer Drug Dispute
U.S. biotechnology company Seagen is looking to vacate an arbitral award nixing its claim to patents for technology used in cancer drugs filed by Japanese drugmaker Daiichi Sankyo Ltd. after their...To view the full article, register now.
Already a subscriber? Click here to view full article